(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 April 2011 (21.04.2011)

PCT

(10) International Publication Number
WO 2011/045080 A2

(51) International Patent Classification:
C07K 16/26 (2006.01)

(21) International Application Number:
PCT/EP2010/006329

(22) International Filing Date:
15 October 2010 (15.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/252,625 16 October 2009 (16.10.2009) US

(71) Applicants *(for all designated States except US)*: **BIOREALITES S.A.S.** [FR/FR]; 2040 Avenue du Père Soulas, F-34 000 Montpellier (FR). **INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)** [FR/FR]; 101 rue de Tolbiac, F-75654 Paris Cedex 13 (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)** [FR/FR]; Campus Gérard-Megie, 3 Rue Michel-Ange, F-75794 Paris Cedex 16 (FR).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PANNEQUIN, Julie** [FR/FR]; 13 rue Henri Barbusse, F-34200 Sète (FR). **BOUDIER, Laure** [FR/FR]; Bâtiment A, 59, Avenue de Bellevue, 03270 Saint-Yorre (FR). **JOUBERT, Dominique** [FR/FR]; 10 rue Gabriel Peri, F-34200 Sète (FR). **HOLLANDE, Frédéric** [FR/FR]; 63 chemin de Ia Déridière, F-34270 Les Matelles (FR).

(74) Agent: **ROQUES, Sarah E.**; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES

(57) **Abstract**: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.

WO 2011/045080 A2